> Pfizer's request for a reissued Lipitor patent was stamped "Rejected" by the U.S. Patent and Trademark Office--but the decision is only preliminary, so the drug maker can still hope for extended exclusivity on the cholesterol drug. FiercePharma [1]
> Spherix's shareholders approved the sale of the company's InfoSpherix subsidiary to The Active Network for $17 million in cash. Release [2]
> They weren't dishonest, just incompetent--or so says an outside investigator who's been looking into Bayer's Trasylol snafu [3]. FiercePharma [4]
And Finally... Japanese stem cell scientist Shinya Yamanaka conducts his ground-breaking research on lean budget. FierceBioresearcher [5]
Links:
[1] http://www.fiercepharma.com/story/pfizers-lipitor-patent-request-rejected/2007-08-17
[2] http://www.fiercebiotech.com/press-releases/press-release-spherix-shareholders-support-companys-focus-naturlose-biotechnology
[3] http://www.fiercebiotech.com/story/bayer-kept-trasylol-safety-study-hidden-from-fda/2006-10-02
[4] http://www.fiercepharma.com/story/investigator-bms-did-not-hide-trasylol-data/2007-08-17
[5] http://www.fiercebioresearcher.com/story/japanese-scientist-operates-lean-budget/2007-08-14